Current cardio-oncology guidelines for the prevention of anthracycline-induced cardiomyopathy advocate for the use of beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), and angiotensin receptor blockers (ARBs), which have demonstrated efficacy in preserving the LVEF during chemotherapy. Here, ACE is linked to cardiomyopathy.